ATLANTA, GA -- (MARKET WIRE) -- February 07, 2007 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced three key promotions within its research and development infrastructure. Charles Kunsch, Ph.D. has been promoted to Vice President Biology; James A. Sikorski, Ph.D. has been promoted to Vice President Medicinal Chemistry; and Cynthia L. Sundell, Ph.D. has been promoted to Vice President Pharmacology. Drs. Kunsch, Sikorski and Sundell all report directly to Rob Scott, M.D., Executive Vice President of Research and Development and Chief Medical Officer at AtheroGenics.
